Guideline 11.8 — Neonatal Cholestasis & Biliary Atresia

KEY TAKEAWAYS

Conjugated (direct) hyperbilirubinemia is NEVER physiologic — it always means liver or biliary disease and demands urgent evaluation.
The one rule that saves livers: any infant still jaundiced beyond 2 weeks (term) — or ~3 weeks in a well, breastfed infant — needs a total AND direct/conjugated bilirubin. Don't attribute prolonged jaundice to breast milk without fractionating.
Biliary atresia is the diagnosis you must not miss — it's the commonest surgical cause of neonatal cholestasis, and the Kasai portoenterostomy works far better the earlier it's done.
Time is liver: Kasai before ~60 days → ~70% establish bile flow; performed after ~90 days → <25%. Referral is frequently too late.
Acholic (pale) stools + dark urine + hepatomegaly in a jaundiced infant = biliary atresia until proven otherwise.
Cholestatic infants need fat-soluble vitamins (A, D, E, K) and nutritional support — and vitamin K to prevent bleeding.

1. Clinical Overview

Clinical Overview

Most prolonged neonatal jaundice is benign unconjugated hyperbilirubinemia (often breast-milk jaundice). But a minority conceals cholestasis — impaired bile formation or flow producing conjugated (direct) hyperbilirubinemia — and among these, biliary atresia is a surgical emergency in slow motion: a progressive obliterative cholangiopathy that, untreated, marches to cirrhosis and liver failure. The tragedy of biliary atresia is that it is treatable early and catastrophic late, yet infants are still frequently referred after the therapeutic window has narrowed.

The entire clinical discipline of this topic reduces to one habit: fractionate the bilirubin in any infant with prolonged jaundice, and act fast on a raised direct fraction.

2. Definitions

Term	Meaning
Cholestasis	Impaired bile formation/flow → conjugated (direct) hyperbilirubinemia (direct bilirubin >1.0 mg/dL, always pathologic).
Prolonged jaundice	Jaundice persisting >14 days (term) / >21 days (preterm).
Biliary atresia (BA)	Progressive fibro-obliterative destruction of the extrahepatic (± intrahepatic) bile ducts.
Acholic stools	Pale/clay-colored stools from absent bile pigment — a red flag for BA.
Kasai portoenterostomy (KPE)	Surgical creation of bile drainage (jejunal loop to the porta hepatis) for BA.

3. Pathophysiology

Pathophysiology

Cholestasis = failure to form or excrete bile → retention of conjugated bilirubin and bile acids → jaundice, pruritus, malabsorption of fat and fat-soluble vitamins, and hepatocellular injury.
Biliary atresia: an inflammatory, fibrosing process obliterates the bile ducts, blocking bile flow → progressive cholestasis → biliary fibrosis → cirrhosis → liver failure. The insult is ongoing, so delay allows irreversible fibrosis even after successful surgical drainage.

Broad causes of neonatal cholestasis: biliary atresia (commonest surgical cause), other obstructive lesions (choledochal cyst), genetic/metabolic (Alagille syndrome, progressive familial intrahepatic cholestasis, alpha-1-antitrypsin deficiency, galactosemia, tyrosinemia, cystic fibrosis), infectious (TORCH, UTI/sepsis), endocrine (hypothyroidism, hypopituitarism), TPN-associated, and idiopathic neonatal hepatitis.

4. Clinical Presentation

Clinical Presentation

Jaundice persisting beyond 2 weeks (the trigger to fractionate bilirubin).
Biliary-atresia red flags: acholic (pale/clay) stools, dark urine, hepatomegaly, and an otherwise often well-appearing, thriving infant early on.
Signs of the underlying cause: dysmorphism (Alagille), cataracts/E. coli sepsis (galactosemia), failure to thrive, coagulopathy/bleeding (fat-soluble vitamin K deficiency).

5. Diagnostic Approach

Diagnostic Approach

1. The non-negotiable first step: in any infant with prolonged jaundice, measure total AND direct/conjugated bilirubin. A direct bilirubin >1.0 mg/dL is pathologic → evaluate for cholestasis. (Consider a stool-color card to flag acholic stools.)

2. Confirm cholestasis and gauge liver function: liver enzymes (GGT — high in obstructive/biliary disease; helps separate from low-GGT familial cholestasis), transaminases, coagulation (PT/INR), albumin, glucose, ammonia (if unwell).

3. Prioritize the time-critical and the treatable:

Biliary atresia workup (urgent): abdominal ultrasound (absent/abnormal gallbladder, triangular cord sign), hepatobiliary scintigraphy (no excretion), liver biopsy (bile-duct proliferation, plugs), and intraoperative cholangiogram (definitive).
Treatable metabolic/infectious causes in parallel: galactosemia (reducing substances, enzyme assay — start lactose-free feeds), hypothyroidism/hypopituitarism, sepsis/UTI, tyrosinemia, alpha-1-antitrypsin, etc.

4. Refer to a pediatric hepatology/surgery center urgently — the workup should not delay evaluation for biliary atresia.

6. Management

Management

Biliary atresia — time-critical surgery

Kasai portoenterostomy (KPE) restores bile drainage; outcome depends heavily on age at surgery.
Before ~60 days: ~70% establish bile flow.
After ~90 days: <25% establish bile flow.
Even after a successful Kasai, many children eventually need liver transplantation — KPE buys native-liver time.
Late/failed diagnosis: proceed to liver transplantation evaluation.

Supportive management of cholestasis (all causes)

Fat-soluble vitamin supplementation (A, D, E, K) — malabsorption is the rule; vitamin K prevents bleeding (VKDB risk is high in cholestasis).
Nutritional support with medium-chain-triglyceride (MCT)-rich formula (MCTs are absorbed without bile) and adequate calories to support growth.
Ursodeoxycholic acid to promote bile flow; manage pruritus.
Treat the specific cause (e.g., lactose-free formula for galactosemia; levothyroxine for hypothyroidism).
Monitor for and manage complications of chronic liver disease (portal hypertension, ascites, growth failure).

6+. NICU Screening, IFALD and Supportive Dosing (Baylor Ed. 33)

The sections above are built around biliary atresia. In a NICU population the commonest cholestasis is different — parenteral-nutrition-associated liver disease — and the screening and supportive detail below is what Baylor specifies for it.

Know which assay your laboratory reports

Conjugated bilirubin is measured two different ways. Direct bilirubin (DB) also captures the "delta" bilirubin fraction and therefore reads higher; conjugated bilirubin (CB) does not. Different hospitals report different ones, so an infant transferred between units can appear to improve or worsen for no clinical reason. CB measurements are preferred for management decisions. Biochemically, neonatal cholestasis is conjugated bilirubin above 1 mg/dL and more than 20% of the total — and cholestasis usually develops well before the infant looks jaundiced, which is why the number, not the appearance, triggers the workup.

Situation	Screening action
Any infant under 4 months admitted to a well-baby or special care nursery	Screening conjugated or direct bilirubin when feasible; in newborns, within 48 hours of age.
Discharged before 2 weeks of life with an initially raised level	Recheck at the 2-week well-child visit.
Still hospitalized with an initially raised level	Repeat at one week of life. If still abnormal, consult the paediatric liver service and work through the investigations stepwise.
Jaundiced at 2 weeks of age (NASPGHAN / ESPGHAN)	Measure total and direct serum bilirubin. Any direct or conjugated hyperbilirubinaemia at 2 weeks warrants immediate referral to a paediatric gastroenterologist.

Intestinal failure-associated liver disease (IFALD)

Definition: conjugated bilirubin ≥2 mg/dL with parenteral nutrition dependence for 14 days or more, in the absence of another cause of cholestasis. It is one of the commonest causes of cholestasis in the NICU. Risk factors: prematurity, the absence of enteral feeds, and any source of inflammation — surgery, infection, small intestinal bacterial overgrowth, SIP, NEC.

Other causes worth naming because they are missed: urinary tract infection and sepsis, congenital heart lesions with left-to-right shunts, transient haemodynamic shifts in critically ill infants, hyperinsulinaemic hypoglycaemia, indeterminate neonatal hepatitis, choledochal cyst, drug-induced liver injury, and the genetic and metabolic diseases — galactosaemia, tyrosinaemia, hypothyroidism, alpha-1-antitrypsin deficiency, Alagille syndrome, neonatal haemochromatosis.

First-line evaluation and when to call genetics

Early evaluation: abdominal ultrasound with Doppler, CBC, PT/INR and blood culture; add an echocardiogram if there is a murmur. If the ultrasound suggests biliary atresia or another obstructive cause, consult the liver team. If it is normal, order focused tests by clinical scenario, with the liver team: specific cultures and serologies for viral hepatitis; plasma amino acids, urine organic acids, acylcarnitine profile, ammonia, lactate and pyruvate for metabolic disease; urine reducing substances, urine succinylacetone, and alpha-1-antitrypsin concentration and phenotype for galactosaemia, tyrosinaemia and AAT deficiency; serum and urine bile acids for bile acid synthesis disorders; free T4 and TSH for hypothyroidism; sweat chloride and mutation analysis for cystic fibrosis; ferritin and transferrin saturation for neonatal haemochromatosis; peripheral smear, blood typing and Coombs for mixed unconjugated and conjugated pictures; hepatobiliary scintigraphy for duct patency; liver biopsy to separate biliary atresia from neonatal hepatitis.

Consider a genetics consult for a family history of conjugated hyperbilirubinaemia or liver disease, dysmorphic features, or a major congenital heart lesion.

Supportive treatment once CB rises above 2 mg/dL, other causes excluded

Feeding: re-establish enteral nutrition as tolerated. Human milk, preterm formula or both suit VLBW infants with cholestasis; preterm and amino-acid-based formulas carry relatively high medium-chain triglyceride content. An amino-acid-based or protein hydrolysate formula is the usual choice when human milk is unavailable or poorly tolerated.
Ursodiol (ursodeoxycholic acid): 15–30 mg/kg/day divided into two or three doses. It is potentially useful in infants with an intact ileocaecal valve who are tolerating feeds of at least 20–40 mL/kg/day. If the terminal ileum has been resected it will not be absorbed efficiently and may cause bile-acid diarrhoea. Withhold it entirely while a bile acid synthesis defect is being evaluated, until the serum bile acid analysis is complete. Continue as long as cholestasis is evident on the liver panel, fat-soluble vitamin levels or serum bile acids. Evidence in IFALD is conflicting — some studies show lower liver enzymes, others no benefit (low to very low certainty, weak recommendation) — and recent work suggests it is poorly absorbed by the preterm intestine.
Fat-soluble vitamins: the multivitamin in PN generally supplies enough A, D and E. If bleeding occurs with a raised INR, give additional vitamin K parenterally at 1 mg/day. Infants on enteral nutrition usually need only a standard multivitamin, though water-soluble formulations of the fat-soluble vitamins may be considered.
Trace elements: copper and manganese are excreted in bile, so in cholestasis they accumulate in the liver and worsen hepatic dysfunction. With PN-associated cholestasis (CB ≥2 mg/dL), give trace elements at half dose daily — then add zinc and copper separately if needed to meet maintenance requirements, because infants will otherwise become copper deficient. Watch enteral zinc in an infant who is copper deficient: excess zinc inhibits copper absorption.

7. Monitoring

Monitoring

Serial bilirubin (total/direct), liver enzymes, synthetic function (INR, albumin), growth.
Fat-soluble vitamin levels and coagulation.
Post-Kasai: bile flow (bilirubin normalization = success), cholangitis surveillance, and transplant evaluation as needed.
Developmental and nutritional follow-up.

8. Complications

Complications

Biliary cirrhosis, portal hypertension, liver failure (untreated/late biliary atresia).
Fat-soluble vitamin deficiency — including vitamin K deficiency bleeding (ICH risk).
Failure to thrive / malnutrition.
Cholangitis (post-Kasai).
Need for liver transplantation.

9. Safety Warnings

Safety Warnings

⚠️ Direct/conjugated hyperbilirubinemia is ALWAYS pathologic — never call it physiologic or "breast-milk jaundice."
⚠️ Fractionate bilirubin in ANY infant jaundiced beyond 2 weeks — this single habit prevents missed biliary atresia.
⚠️ Time is liver — refer suspected biliary atresia urgently; the Kasai window closes fast.
⚠️ Give vitamin K — cholestatic infants are at high risk of catastrophic bleeding.
⚠️ Acholic stools + dark urine = biliary atresia until proven otherwise.
⚠️ Don't forget treatable causes (galactosemia, hypothyroidism, sepsis) in parallel.

10. Common Mistakes

Common Mistakes

Not fractionating bilirubin in prolonged jaundice (the cardinal error).
Attributing prolonged jaundice to breast milk without checking a direct bilirubin.
Late referral of biliary atresia (missing the Kasai window).
Omitting fat-soluble vitamins / vitamin K in a cholestatic infant.
Ignoring acholic stools.
Failing to pursue treatable metabolic/infectious causes promptly.
Under-supporting nutrition (missing MCT-based feeding).

11. Clinical Pearls

Clinical Pearls

💡 "Jaundice past two weeks? Split the bilirubin."
💡 Conjugated hyperbilirubinemia is a diagnosis of disease, not a variant of normal.
💡 Pale stools are a surgical red flag — a stool-color card catches them.
💡 Kasai before 60 days — every week matters.
💡 Cholestasis starves the baby of fat-soluble vitamins — replace A, D, E, K (and prevent bleeding with K).
💡 MCT formula feeds the infant when bile can't.

12. Summary Table

Summary Table

Domain	Bottom line
Screen	Prolonged jaundice (>2 wk term / >3 wk breastfed) → total + direct bilirubin
Cholestasis	Direct bilirubin >1.0 mg/dL = pathologic (never physiologic)
Red flags	Acholic stools, dark urine, hepatomegaly
Top surgical cause	Biliary atresia
BA workup	US (triangular cord/absent GB), scintigraphy, biopsy, intraoperative cholangiogram (definitive)
BA treatment	Kasai portoenterostomy — before ~60 days (≥90 days → poor bile flow); many still need transplant
Supportive	Fat-soluble vitamins (A,D,E,K), MCT formula, ursodeoxycholic acid, treat pruritus
Treatable causes	Galactosemia (lactose-free), hypothyroidism, sepsis/UTI, tyrosinemia, A1AT
Complication to prevent	Vitamin K deficiency bleeding (give vitamin K)

13. Step-by-Step Bedside Algorithm

INFANT jaundiced BEYOND 2 WEEKS (term) / ~3 weeks (well, breastfed)
        │
        ▼
MEASURE TOTAL + DIRECT (CONJUGATED) BILIRUBIN   ← the non-negotiable step
        │
        ├─ Direct NORMAL (unconjugated jaundice, well) → likely breast-milk jaundice;
        │                                                 reassess if persists/atypical
        │
        └─ Direct ELEVATED (>1.0 mg/dL) → CHOLESTASIS (always pathologic)
                    │
                    ▼
   Assess: stool color (acholic?), urine (dark?), hepatomegaly
   Labs: GGT, transaminases, PT/INR, albumin, glucose (+ give VITAMIN K)
                    │
                    ▼
   URGENT parallel workup + refer to pediatric hepatology/surgery
        ├─ Biliary atresia workup: US (triangular cord/absent GB) → scintigraphy →
        │   biopsy → INTRAOPERATIVE CHOLANGIOGRAM (definitive)
        └─ Treatable causes: galactosemia (lactose-free), hypothyroidism, sepsis/UTI, tyrosinemia, A1AT
                    │
        ┌───────────┴───────────┐
        ▼                       ▼
   BILIARY ATRESIA         Other cholestasis
   → KASAI (ideally <60 d)  → treat specific cause
   → many still need         → supportive: fat-soluble vitamins, MCT formula, UDCA
     transplant
                    │
                    ▼
   Supportive care for all: nutrition, fat-soluble vitamins, monitor synthetic function/growth

14. References to Verify

Confirm each against the primary source before clinical or published use.

1.Primary guideline: Fawaz R, et al.; NASPGHAN/ESPGHAN. Guideline for the Evaluation of Cholestatic Jaundice in Infants — Joint Recommendations of NASPGHAN and ESPGHAN. J Pediatr Gastroenterol Nutr. 2017;64(1):154–168. (Fractionate bilirubin by 2–3 weeks — verify.)
2.Kasai timing: biliary-atresia outcome data by age at portoenterostomy (native-liver survival vs age). (Verify the <60 vs >90 day figures.)
3.Stool-color-card screening: national programs (e.g., Taiwan) improving early diagnosis. (Verify.)
4.Direct-bilirubin screening: Harpavat S, et al. universal direct-bilirubin screening for biliary atresia. (Verify.)
5.Nutritional/vitamin management: cholestasis supportive-care references (fat-soluble vitamins, MCT, UDCA). (Verify dosing.)

Back to Clinical Guideline Hubs

Chapter 11.8 — Neonatal Cholestasis & Biliary Atresia